US OptionsDetailed Quotes

AZN250502C88000

Watchlist

0.00
0.000.00%

15min DelayClose Apr 28 09:30 ET

0.00High0.00Low

AstraZeneca Stock Discussion

Teddy123

Apr 21 19:07

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival vs. THP as 1st-line therapy

$AstraZeneca (AZN.US)$
First Major Breakthrough in 10 Years: ENHERTU Combo Outperforms Standard HER2+ Breast Cancer Treatment

Teddy123

Apr 21 16:02

ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Posit

$AstraZeneca (AZN.US)$
First Major Breast Cancer Treatment Breakthrough in 10 Years: ENHERTU Trial Reveals Superior Efficacy

Teddy123

Apr 8 14:41

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

$AstraZeneca (AZN.US)$
Revolutionary AI Technology Detects Lung Cancer Mutations Without Invasive Testing

Teddy123

Apr 8 14:41

DATROWAY® Approved in the EU for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

$AstraZeneca (AZN.US)$
New Breast Cancer Drug DATROWAY Shows 37% Better Survival Rates in EU Approval

Movers and Shakers

Apr 3 20:16

Columns Today's Pre-Market Movers and Top Ratings | TSLA, AAPL, AZN and More

Morning Movers
Gapping Up
$Diageo (DEO.US)$ shares rose 4.6% in pre-market trading, as U.S. tariffs avoided the worst-case scenario for spirits. Goodbody noted no new duties on Canadian and Mexican imports, while Jefferies highlighted the avoidance of a potential 200% tariff on EU alcohol, benefiting European distillers.
Pharmaceutical shares are up in pre-market trading as drug imports could be exempt from the new 'reciprocal ta...

With the approaching of the exemption from auto tariffs, how will Trump fulfill his promise?

Teddy123

Mar 31 19:22

IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer

$AstraZeneca (AZN.US)$
Breakthrough: First-Ever FDA-Approved Immunotherapy Shows 32% Better Outcomes in Bladder Cancer

Teddy123

Mar 26 12:33

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

$AstraZeneca (AZN.US)$
Major Breakthrough: AstraZeneca's TAGRISSO Extends Lung Cancer Survival to Nearly 5 Years

Teddy123

Feb 28 21:12

$AstraZeneca (AZN.US)$
ENHERTU Shows 38% Reduced Death Risk in Breast Cancer - EU Approval Now One Step Closer

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Teddy123

Feb 26 20:14

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$AstraZeneca (AZN.US)$
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?

Ryand83

Feb 25 08:28

$LumiraDx (LMDXF.US)$ if we started bringing awareness to X FB and other social media platforms we could probably win this fight. I stayed in Lumiradx because I figured if $AstraZeneca (AZN.US)$ had scooped it up we would have been jipped. $ROCHE HOLDING AG (RHHBY.US)$ seemed like a better fit as they have a plethora of innovative solutions to revitalize companies. 350m seems like an $Abbott Laboratories (ABT.US)$ or $Johnson & Johnson (JNJ.US)$ move to me and I don't buy it. Not from Roche.

No comment yet